Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Mevo Health vs NowPatient

Mevo Health
Graded #327

Lower grade

vs+5.299999999999997
NowPatient
Graded #222

Higher grade

The verdict

NowPatient takes it — 65.5/100 to 60.2/100.

NowPatient grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NowPatient is a US-UK telehealth platform offering brand-name GLP-1 weight management access including Mounjaro, Wegovy (injection and oral tablet), and Saxenda.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMevo Health +21
56
35
Dose & formulationNowPatient +10
83
93
Clinical oversightNowPatient +19
67
86
Labs & monitoringNowPatient +2
52
54
FulfillmentNowPatient +13
57
70
Contract termsNowPatient +35
20
55
Mevo Health · left barNowPatient · right bar

The numbers

MetricMevo HealthNowPatient
WeighScore60.2/10065.5/100
GradeCC
Scorecard rank#327#222
Semaglutide$199/mo (all doses, compounded)$1,349/mo (brand Wegovy)
Tirzepatide$259/mo (all doses, compounded)$1,069/mo (brand Mounjaro, promotional rate)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualYesYes
Mevo Health

Graded #327 · C

Strengths

  • LegitScript verification badge on multiple pages
  • Publishes the FDA compounded-medication disclaimer
  • Four named board-certified physicians disclosed (Wasef, Suppa, Sakla, Chikando)
  • Both semaglutide and tirzepatide in injection and oral-tablet forms — rare in DTC
  • Public entry-level pricing surfaced

Where it loses points

  • States served not listed on any public page
  • Pharmacy partners not named (only '503A U.S. compounding pharmacies' with unlabeled logos)
  • No formal Medical Director role disclosed
  • Only 'as low as' entry pricing shown — no per-dose itemization
  • No SOC 2 certification claimed
NowPatient

Graded #222 · C

Strengths

  • Free telehealth consultation — you only pay for the medication
  • Brand-name Mounjaro, Wegovy injection, Wegovy oral tablet, and Saxenda all available
  • One of the few platforms offering Wegovy in both injection and oral pill form
  • No compounded options — every drug is FDA-approved brand-name

Where it loses points

  • Cash-pay pricing tracks full brand list price (~$1,000–$1,350/mo)
  • No compounded semaglutide or tirzepatide (usually the cheaper route)
  • State availability determined during intake, not shown upfront
  • Does not offer Foundayo (orforglipron)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard